OS Therapies Inc
OSTXNYSE
$1.53
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↓ -8.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$59.2M
Enterprise Value
$59.2M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$35.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
325.9%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-8.9%
Company profile
OS Therapies Incorporated is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. We were formed as a Delaware limited liability company on April 12, 2018 under the name OS Therapies, LLC. On June 24, 2019, we converted from a limited liability company to a Delaware corporation and changed our name to OS Therapies Incorporated. We presently conduct all of our operations remotely. Our registered corporate address is 15825 Shady Grove Road, Suite 135, Rockville, Maryland.
- CEO
- Paul A. Romness
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Maryland
- Website
- ostherapies.com
Earnings
OSTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.27↑ +50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$4.3M | -$6.8M | -$28.7M |
| Net income | -$7.8M | -$8.9M | -$28.8M |
| Diluted EPS | -$1.46 | -$1.28 | -$0.98 |
| Operating cash flow | -$3.0M | -$7.3M | -$14.2M |
| Free cash flow | — | — | — |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$779,800.00 | -$2.4M | -$3.0M | -$5.0M | -$4.8M | -$6.9M | -$12.0M | -$10.2M |
| Net income | -$1.6M | -$2.9M | -$3.0M | -$3.9M | -$4.5M | -$6.9M | -$13.5M | -$10.4M |
| Diluted EPS | -$0.26 | -$0.18 | -$0.59 | -$0.18 | -$0.19 | -$0.21 | -$0.40 | -$0.27 |
| Operating cash flow | -$881,191.00 | -$3.4M | -$2.4M | -$3.4M | -$2.4M | -$4.7M | -$3.7M | -$4.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.